New hope for lung cancer patients with scarred lungs: precision radiation trial underway
NCT ID NCT03485378
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase II trial tests a precise type of radiation called SABR in 39 people with early-stage non-small cell lung cancer who also have interstitial lung disease (lung scarring). The goal is to see if this treatment can control the cancer while keeping side effects manageable. Participants are divided into groups based on the severity of their lung disease, and the study tracks survival, tumor control, and cough severity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Stereotactic ablative radiotherapy (SABR)
What this could lead to
If successful, this could show that precise radiation is a safe and effective option for lung cancer patients who also have interstitial lung disease, offering a treatment path where surgery is not possible.
What could go wrong
This is a small, early-phase study with only 39 participants, so results may not apply to everyone. Radiation can cause lung inflammation or scarring, especially in patients with existing lung disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alberta Health Services, Cross Cancer Institude
Edmonton, Alberta, T6G 1Z2, Canada
-
CHUM Université de Montréal
Montreal, Quebec, H2X 0A9, Canada
-
Edinburgh Cancer Centre, Western General Hospital
Edinburgh, EH4 2XU, United Kingdom
-
London Regional Cancer Program of the Lawson Health Research Institute
London, Ontario, N6A 4L6, Canada
-
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5, Canada
-
UHN Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada